Preclina is a non-clinical CRO specialized in autoimmune and inflammatory disorders, providing the utmost quality services for novel drug development at the lightning speed, highest quality, and reasonable cost.
In the global market of immune disease therapeutics, which shows explosive growth, Preclina Inc is a leading company that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds.
Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation and effectively designed support for drug development processes. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed.
